News | August 01, 2024
Ajanta Pharma posts Q1 FY25 consolidated PAT at Rs. 245.77 Cr
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
Ajanta Pharma has reported total income of Rs. 1,171.39 crores during the period ended June 30, 2024
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Fredun Pharmaceuticals has reported total income of Rs. 78.81 crores during the period ended June 30, 2024
Themis Medicare has reported total income of Rs. 123.95 crores during the period ended June 30, 2024
Granules India has reported total income of Rs. 1181.92 crores during the period ended June 30, 2024
These gummies are specially formulated for both kids and adults to nourish the eyes and promote optimal vision development
Decision on EU marketing authorisation for this population expected by September 2024
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
GSK and Flagship to jointly fund up to $150 million upfront
Access to breast milk for sick newborns admitted in intensive care units plays a lifesaving role
Subscribe To Our Newsletter & Stay Updated
